287 related articles for article (PubMed ID: 37435267)
41. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
[TBL] [Abstract][Full Text] [Related]
42. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
Jamieson L; Serenata C; Makhubele L; Sokhela S; Mashabane N; Akpomiemie G; Johnson LF; Venter WDF; Meyer-Rath G
AIDS; 2021 Dec; 35(Suppl 2):S173-S182. PubMed ID: 34848584
[TBL] [Abstract][Full Text] [Related]
43. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
[TBL] [Abstract][Full Text] [Related]
44. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Dooley KE; Kaplan R; Mwelase N; Grinsztejn B; Ticona E; Lacerda M; Sued O; Belonosova E; Ait-Khaled M; Angelis K; Brown D; Singh R; Talarico CL; Tenorio AR; Keegan MR; Aboud M;
Clin Infect Dis; 2020 Feb; 70(4):549-556. PubMed ID: 30918967
[TBL] [Abstract][Full Text] [Related]
45. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
46. Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses.
Benson P; Kuretski J; Donovan C; Harper G; Merrill D; Metzner AA; Mycock K; Wallis H; Brogan AP; Patarroyo J; Oglesby A
Infect Dis Ther; 2024 Apr; 13(4):875-889. PubMed ID: 38570444
[TBL] [Abstract][Full Text] [Related]
47. Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.
Chapola JC; Lee F; Bula A; Rosenberg NE; Tseka J; Chagomerana M; Hosseinipour MC; Tang JH
BMC Womens Health; 2023 Sep; 23(1):478. PubMed ID: 37689628
[TBL] [Abstract][Full Text] [Related]
48. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
49. Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis.
Rodrigues VA; Ceccato MDGB; de Oliveira Costa J; Almeida-Brasil CC; Silveira MR; Afonso Reis E
AIDS Care; 2023 Jul; 35(7):976-981. PubMed ID: 35635108
[TBL] [Abstract][Full Text] [Related]
50. Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia.
Belay YB; Ali EE; Chung KY; Gebretekle GB; Sander B
Pharmacoecon Open; 2021 Dec; 5(4):655-664. PubMed ID: 34133017
[TBL] [Abstract][Full Text] [Related]
51. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F; Arribas JR; Miró JM; Costa MA; González J; Rubio R; Peña JM; Torralba M; Lonca M; Lorenzo A; Cepeda C; Vázquez JJ; Gatell JM;
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):343-50. PubMed ID: 15097150
[TBL] [Abstract][Full Text] [Related]
52. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
53. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
54. Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
Kouamou V; Washaya T; Ndhlovu CE; Manasa J
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766288
[TBL] [Abstract][Full Text] [Related]
55. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era.
McCluskey SM; Pepperrell T; Hill A; Venter WDF; Gupta RK; Siedner MJ
AIDS; 2021 Dec; 35(Suppl 2):S127-S135. PubMed ID: 34848579
[TBL] [Abstract][Full Text] [Related]
56. Effect of Dolutegravir-Based First-Line Antiretroviral Therapy on Mother-to-Child Transmission of HIV Among HIV-Exposed Infants in Ethiopia: a Before-and-After Study.
Facha W; Tadesse T; Wolka E; Astatkie A
HIV AIDS (Auckl); 2024; 16():203-215. PubMed ID: 38765704
[TBL] [Abstract][Full Text] [Related]
57. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.
Modongo C; Wang Q; Dima M; Matsiri O; Kgwaadira B; Rankgoane-Pono G; Shin SS; Zetola NM
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):111-115. PubMed ID: 31335593
[TBL] [Abstract][Full Text] [Related]
58. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Glass TR; Amstutz A; Tschumi N; Belus JM; Klimkait T; Labhardt ND
HIV Med; 2023 Feb; 24(2):153-162. PubMed ID: 35730213
[TBL] [Abstract][Full Text] [Related]
59. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
Jarrin I; Suarez-Garcia I; Moreno C; Tasias M; Del Romero J; Palacios R; Peraire J; Gorgolas M; Moreno S;
Antivir Ther; 2019; 24(3):167-175. PubMed ID: 30747107
[TBL] [Abstract][Full Text] [Related]
60. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
